Basic Information
| LncRNA/CircRNA Name | DLX6-AS1 |
| Synonyms | DLX6-AS1, DLX6-AS, DLX6AS, Evf-2, NCRNA00212 |
| Region | GRCh38_7:96955141-97014065 |
| Ensemble | ENSG00000231764 |
| Refseq | NR_015448 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RNAi, other |
| Sample | pancreatic cancer tissues and cell lines (CAPAN-1,BxPC-3, SW 1990 and PANC-1) |
| Expression Pattern | up-regulated |
| Function Description | The high expression of DLX6-AS1 was observed in pancreatic cancer tissues, and high expression of DLX6-AS1 was positively correlated with larger tumor size, advanced TNM stage and lymph node metastasis. Knockdown of DLX6-AS1 dramatically impaired cancer cell proliferation, migration and invasion. MiR-181b was the downstream target of DLX6-AS1. Knockdown of miR-181b reversed the suppression of cell viability, migration and invasion abilities caused by DLX6-AS1 knockdown. MiR-181b was found to target Zinc finger E-box-binding homeobox 2 and to modulate epithelial-mesenchymal transition. Furthermore, DLX6-AS1 knockdown inhibited tumor growth and tumor metastasis in vivo. |
| Pubmed ID | 30250401 |
| Year | 2018 |
| Title | LncRNA DLX6-AS1 Promoted Cancer Cell Proliferation and Invasion by Attenuating the Endogenous Function of miR-181b in Pancreatic Cancer |
External Links
| Links for DLX6-AS1 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |